IL-1 antagonist formulations

/Home/Lyophilization and Protein Formulation Patents/Patent Articles - Lyophilization/Patent Pending - Lyophilization

IL-1 antagonist formulations
Engineering Village
Publication number: US20060040852

Application number: 11205935

Unstandardized application number: 205935

Patent authority: US

Kind: A1 - Utility Patent Application

Title: IL-1 antagonist formulations

Inventors: Goolcharran, Chimanlall (US) ; Bowers, Katherine (US) ; Dix, Daniel (US)

Publication date: 02/23/2006

Publication year: 2006

Filing date: 08/17/2005

Abstract: Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO:10.

Document type: US Application

IPC-8 Code: A61K 38/17 SECTION A HUMAN NECESSITIES
MEDICAL OR VETERINARY SCIENCE; HYGIENE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES bringing into special physical form ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; compounds per se , , , ; soap compositions ; micro-organisms per se
Medicinal preparations containing peptides peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergoline-based peptides ; containing macromolecular compounds having statistically distributed amino acid units ; medicinal preparations containing antigens or antibodies ; medicinal preparations characterised by the non-active ingredients, e.g. peptidesas drug carriers, 6
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof 6
from animals; from humans 6

US Classification: 514/2 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI

Database: US Patents

Compilation and indexing terms, ? 2006 LexisNexis Univentio B.V.
This is a subscription site. You will need to subscribe to Engineering Village 2 to view the details.